CAM2029 is a novel, octreotide subcutaneous depot designed for convenient, once-monthly self-administration by patients and enhanced octreotide plasma exposure with the potential for effective disease control and improved quality of life of patients.
"The acceptance of the market authorisation application for CAM2029 for review by the
The MAA submission for CAM2029 is supported by data from seven clinical trials, including two Phase 3 studies within the ACROINNOVA program.1,2 A new drug application for CAM2029 has earlier been submitted to the
CAM2029 for the treatment of acromegaly has been granted orphan drug designation status in the EU.
For more information
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com
About acromegaly
Acromegaly is a rare, slowly progressive disease, typically caused by a tumor of the pituitary gland producing excess growth hormone and stimulating increased insulin growth factor-1 (IGF-1) levels. This results in abnormal growth of bone and tissue, enlarged hands, feet, facial features and inner organs, and symptoms such as fatigue, joint pain, headache, visual field defects, excessive sweating and paresthesia.3 Inadequate biochemical and symptom control can have detrimental impacts on quality of life and mortality of patients with acromegaly.4-9 The prevalence of acromegaly is estimated to about 60 cases per million.10
About CAM2029
Octreotide SC depot, CAM2029, is an investigational, ready-to-use octreotide for subcutaneous administration under development for the treatment of acromegaly, as well as gastroentero-pancreatic neuroendocrine tumors (GEP-NET), and polycystic liver disease (PLD). CAM2029 is designed for enhanced octreotide exposure and convenient, once-monthly administration with a prefilled autoinjector pen to facilitate easy self-administration by patients.
The CAM2029 clinical program for acromegaly comprises of seven clinical trials, including four Phase 1 studies, one Phase 2 study, and two Phase 3 studies within the ACROINNOVA clinical program. CAM2029 has demonstrated an approximate five-fold higher bioavailability compared to the currently approved, long-acting, intramuscular (IM) octreotide.11 In the Phase 3 ACROINNOVA program, CAM2029 showed superior biochemical control compared to placebo as well as improvements in symptom control, treatment satisfaction, and quality of life compared to standard of care with first-generation somatostatin receptor ligands (SRLs).The safety profile of CAM2029 was similar to that of approved injectable octreotide and lanreotide products with no new or unexpected findings.
About
References
- Clinicaltrials.gov: NCT04076462
- Clinicaltrials.gov: NCT04125836
- Colao A., et al. Acromegaly. Nat Rev Dis Primers. 2019;5(1):20.
- Webb SM, et al. Quality of Life in Acromegaly. Neuroendocrinology. 2016;103(1):106-111.
- Strasburger CJ, et al. Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. Eur J Endocrinol. 2016 Mar;174(3):355-62.
- Melmed S., et al. Causes and clinical manifestations of acromegaly, UpToDate, last updated
May 2020 , accessedMay 2023 . - Melmed S., et al. Diagnosis of acromegaly, UpToDate, last updated
Dec 2021 , accessedMay 2023 . - Katznelson L., et al. Acromegaly: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99(11):3933-51.
- Holdaway IM, et al. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89(2):667-74
- Crisafulli S., et al. Global epidemiology of acromegaly: a systematic review and meta-analysis. Eur J Endocrinology. 2021; 185:251-63.
- Prescribing Information SANDOSTATIN® LAR, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021008Orig1s047Corrected_lbl.pdf
This information is information that
https://news.cision.com/camurus-ab/r/camurus-receives-ema-acceptance-of-maa-filing-for-octreotide-sc-depot--cam2029--for-the-treatment-of,c3986618
https://mb.cision.com/Main/13456/3986618/2817136.pdf
(c) 2024 Cision. All rights reserved., source